A Study of Nemonoxacin Malate Sodium Chloride Injection Administered by Intravenous Infusion
A Phase I Clinical Study of Nemonoxacin Malate Sodium Chloride Injection Administered by Intravenous Infusion
Sponsor: TaiGen Biotechnology Co., Ltd.
Listed as NCT01529957, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by TaiGen Biotechnology Co., Ltd., it has been updated 7 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1
First recorded
Sep 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- TaiGen Biotechnology Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Beijing, China, Chengdu, China, Chongqing, China, Dalian, China, Gansu, China, Guangzhou, China, Hangzhou, China, Hunan, China, Jiangxi, China, Liaoning, China and 6 more location s